Clinical-anamnestic features and quality of life in women with endometrial pathology on the background of uterine myoma.

V. L. Dronova, S. M. Kornienko

Abstract


A total of 325 women 35-55 years old suffering from various forms of endometrial pathology were examined. It was found that 110 (33.8%) patients had combination of endometrial pathology and uterine myoma. They made up the main group (group MM), the reference group consisted of 215 women without uterine myoma (group K). It was established that group with uterine myoma is characterized by increased extragenital morbidity: cardiomyopathy (p<0.009), hypertension (p<0.03), obesity stage III-IV (p<0.006), iron-deficiency anemia (p<0,02), vegetative-vascular dystonia (p<0,03) and nervous system diseases (p<0,01) were significantly more common. The presence of uterine myoma is associated with increased risk of recurrence of endometrial hyperplasia and polyps. These data suggest that in the pathophysiology of uterine myoma in women of late reproductive and premenopausal age with  endometrial pathology somatic and somatoform disorders play a more significant role than concomitant or previous genital pathology. In late reproductive age and menopause period endometrial lesions are combined with uterine myoma in every third patient. Somatic factors have a greater impact on the development of uterine myoma than reproductive. The presence of uterine myoma is an additional criterion of reduceof quality of life and burdens the prognosis of treatment of endometrial pathology in late reproductive age and premenopausal period.


Full Text:

PDF

References


1. Dikareva LV, Shvarev ЕG, Ukhanova YY, Ab­ghalilova AR, Romakhova TV. Hyperplastic processes of mioendometrium: features of the pathogenesis and approaches to diagnosis. Basic research. 2013;9:182-7.

2. Lapina IA, Nasyrova NI. Optimization of treat­ment in patients with uterine diseases can. Gynecology. 2015;4:27-31.

3. Kogan EA, Askol'skaja SI, Burykina PN, Demura TА, Fajzulina NM, Karavaev YuE, Popov YuV, Bulynina TV. Obstetrics and Gynecology. 2013;8:46-51.

4. Chilova AA, Fedotovskih IV, Vorontsova AV, Zvychajnyj MA. Perimenopause and hyperplastic synd­rome of reproductive system – treatment and reha­bi­litation for women.Urals medical journal. 2012;13:100-6.

5. Sheshukova NA, Makarov IO, Borovkova EI, Fedotova AS, Bykova OA. Prognostic factors of deve­lopment of hyperplastic processes of endometrium during perimenopause. Russian Bulletin of obstetrician-gyne­cologist. 2011;11(4):13-16.

6. Pestrykova TYu, Yurasov IV, Bezrukova NI, Yurasova EA. Rational management of patients with uterine myoma and endometrial pathology. Far East medical journal. 2005;3:51-56.

7. Sidorova IS, Sheshukova NA, Zakablukova SV. Endometrial pathology in the presence of uterine fibroids. Gynecology. 2006;8(4):63-67.

8. Tikhomirov AL, Kazenashev VV. Associative non-malignant endometrial hyperplasias: rational therapeutic approach. Problems of reproduction. 2016;2:51-55.

9. Dalton-Brewer N. The Role of Complementary and Alternative Medicine for the Management of Fibroids and Associated Symptomatology. Curr Obstet Gynecol Rep. 2016;5:110-18.

10. Sparic R, Mirkovic L, Malvasi A, Tinelli A. Epi­demiology of Uterine Myomas: A Review. Int J Fertil Steril. 2016;9(4):424-35.

11. Khan AT, Shehmar M, Gupta JK. Uterine fib­roids: current perspectives. Int J Womens Health. 2014;6:95-114.

12. Ciarmela P. Ciavattini A. Management of leio­myomas in perimenopausal women. Maturitas. 2014;78(3):168-73.

13. Wise LA, Laughlin-Tommaso S.K. Epidemiology of Uterine Fibroids: From Menarche to Menopause. Clin Obstet Gynecol. 2016;59(1):2-24.


GOST Style Citations


  1. Гиперпластические процессы миоэндометрия: особенности патогенеза и подходы к диагностике / Л.В. Дикарева, Е.Г. Шварёв [и др.] // Фундаменталь­ные исследования. – 2013. – № 9. – С. 182-187.
  2. Лапина И.А. Оптимизация лечения пациенток с пролиферативными заболеваниями матки / И.А. Ла­пина, Н.И. Насырова // Гинекология. – 2015. – № 4. – С. 27-31.
  3. Морфофункциональное состояние эндометрия у больных миомой матки репродуктивного возраста / Е.А. Коган, С.И. Аскольская [и др.] // Акушерство и гинекология. – 2013. – № 8. – С. 46-51.
  4. Перименопауза и гиперпластические синдром репродуктивной системы-тактика лечения и реаби­литации женщин / А.А. Чилова, И.В. Федотовских, А.В. Во­ронцова, М.А. Звычайный // Урал. мед. журнал. – 2012. – № 13. – С. 100-106.
  5. Прогностические факторы развития гипер­пластических процессов в эндометрии в период пери­менопаузы / Н.А. Шешукова, И.О. Макаров [и др.] // Рос. вестник акушера-гинеколога. – 2011. – № 4. – С. 13-16.
  6. Рациональная тактика ведения больных с миомой матки и патологией эндометрия / Т.Ю. Пес­трикова, И.В. Юрасов, Н.И. Безрукова, Е.А. Юрасова // Дальневосточный мед. журнал. – 2005. – № 3. – С. 51-56.
  7. Сидорова И.С. Патология эндометрия при наличии миомы матки / И.С. Сидорова, Н.А. Ше­шукова, С.В. Закаблукова // Гинекология. – 2006. – Т. 8, № 4. – С. 63-67.
  8. Тихомиров А.Л. Сочетанные доброкачествен­ные гиперплазии матки. Рациональный лечебный подход / А.Л. Тихомиров, В.В. Казенашев // Пробле­мы репродукции. – 2016. – №2. – С. 51-55.
  9. Dalton-Brewer N. The Role of Complementary and Alternative Medicine for the Management of Fibroids and Associated Symptomatology / N. Dalton-Brewer // Curr. Obstet. Gynecol. Rep. – 2016. – N 5. – Р. 110-118.
  10. Epidemiology of Uterine Myomas: A Review / R. Sparic, L. Mirkovic, A. Malvasi, A. Tinelli // Int. J. Fertil Steril. – 2016. – Vol. 9, N 4. – Р. 424-435.
  11. Khan A.T. Uterine fibroids: current perspectives / A.T. Khan, M. Shehmar, J.K. Gupta // Int. J. Womens Health. – 2014. – N 6. – Р. 95-114.
  12. Management of leiomyomas in perimenopausal women / P. Ciarmela, A. Ciavattini [et al.] // Maturitas. – 2014. – Vol. 78, N 3. – Р. 168-173.
  13. WiseL.A.Epidemiology of Uterine Fibroids: From Menarche to Menopause /L.A.Wise, S.K. Lau­ghlin-Tommaso // Clin. Obstet. Gynecol. – 2016. – Vol. 59, N 1. – Р. 2-24. 


Refbacks

  • There are currently no refbacks.